tiprankstipranks
Advertisement
Advertisement

Haoxi Health CEO Boosts Control with $720,000 Class B Share Purchase

Story Highlights
  • Haoxi Health struck a May 18 deal to sell 40 million Class B shares to CEO Zhen Fan for $720,000, at a slight premium to its Nasdaq Class A price, to fund working capital and general corporate needs.
  • The related-party financing, approved by Haoxi Health’s audit committee as fair and arm’s-length, is expected to close around May 19, 2026 and will lift CEO Zhen Fan’s stake to about 83.83% of the company’s voting power.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Haoxi Health CEO Boosts Control with $720,000 Class B Share Purchase

Meet Samuel – Your Personal Investing Prophet

An announcement from Haoxi Health Technology Limited Class A ( (HAO) ) is now available.

On May 18, 2026, Haoxi Health Technology Limited entered into a securities purchase agreement with its chief executive and board chairman, Zhen Fan, under which the company agreed to issue 40,000,000 new Class B ordinary shares at $0.018 per share for total proceeds of $720,000. The price was set slightly above the closing price of its Class A shares on Nasdaq that day, with the transaction relying on exemptions from U.S. registration rules and closing expected around May 19, 2026.

The company plans to use the cash infusion for working capital and general corporate purposes, strengthening its liquidity without accessing public markets. Because the deal is a related-party transaction, the board’s audit committee reviewed potential conflicts, approved the terms as fair and arm’s-length, and noted that upon closing Zhen Fan will control about 83.83% of the company’s total voting power, further consolidating insider control and potentially influencing future corporate governance dynamics for existing shareholders.

Spark’s Take on HAO Stock

According to Spark, TipRanks’ AI Analyst, HAO is a Neutral.

The overall score reflects a combination of strong valuation, with the stock appearing undervalued, and moderate financial performance, highlighted by revenue growth but hampered by cash flow issues. Technical analysis indicates a lack of strong momentum, contributing to the overall risk profile.

To see Spark’s full report on HAO stock, click here.

More about Haoxi Health Technology Limited Class A

Haoxi Health Technology Limited is a Cayman Islands-incorporated company operating in the health technology sector, with its principal executive offices in Beijing’s Chaoyang District. The company has a dual-class share structure comprising Class A and Class B ordinary shares listed on Nasdaq, and it focuses on capital markets financing to support its ongoing health-related operations and growth.

Average Trading Volume: 21,537,093

Technical Sentiment Signal: Sell

Current Market Cap: $1.34M

See more insights into HAO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1